NCT06775041
Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients with Hutchinson-Gilford Progeria Syndrome (HGPS)
Phase: Phase 2
Role: Lead Sponsor
Start: Jan 31, 2025
Completion: Dec 31, 2025